New Exclusive to SŌMA Regenerative therapies: APAG, Liquid CGF and Personalised Autologous Cream
M.Biom
By Dr Muhammad Nadim (M.Biomed) · Medically reviewed by Dr Shirley Yuliana Kwee, MBChB (Glasgow), GDFM (NUS) · Updated 24 September 2026
Smoother-looking skin, subtle volume and a skincare plan made for one person are different goals. They should not all lead to the same treatment.
SŌMA is expanding its exclusive autologous treatments in Uluwatu, Bali, with APAG plasma gel, liquid CGF and personalised blood-derived topical creams. These additions sit alongside our existing PRP and Autologous Exosome treatments, giving patients more specific options to achieve their aesthetic and anti-ageing goals.
The new treatments are exclusive to SŌMA and allow us to provide advanced regenerative options that match specific patient concerns. It is not an invitation to combine every available treatment or to assume that the newest option is always the right one.
What is new, at a glance?
APAG is a plasma-protein gel mixed with the CGF considered for selected volume concerns. LPCGF, or liquid CGF, is a liquid blood-derived preparation used in skin-focused protocols. An autologous cream combines a formulated topical base with a specified fraction prepared from the same patient's blood CGF material.
These are three different formats: a gel, a liquid and a topical cream. The first two are described in technical aesthetic protocol information; the topical approach also has a small body of research.
APAG: a separate conversation about subtle volume
A patient concerned about volume loss may not be asking for a smoother skin surface. They may want a modest change in contour while still looking like themselves.
APAG provides an autologous plasma-gel option for that discussion. The consultation considers the area, the desired change, tissue characteristics and the alternatives. It also covers the material's limitations, uncertainty about longevity, and injection risks.
Research into related plasma-gel techniques includes a randomised study in atrophic acne scars. That study used a particular preparation and treatment course. It supports interest in the category, not a claim that SŌMA's APAG reproduces every published result or replaces all other fillers.
Liquid CGF: an option within a skin-quality plan
Uneven texture, fine lines and the appearance of tired skin can have different causes. At SŌMA, we start by separating the concern from the treatment name.
LPCGF is a liquid preparation from the CGF material. It can be discussed within selected skin-quality and mesotherapy protocols. It differs from conventional PRP.
Research on liquid CGF includes laboratory work involving periodontal cells. Such studies help explain scientific interest, but do not settle how much a patient's facial appearance will change. That distinction belongs in an honest consultation.
A skin plan may also involve established skincare or a procedure directed at the underlying concern. Adding a blood-derived preparation is a decision to justify, rather than a requirement for every patient.
Personalised cream: extending the care conversation beyond the appointment
The new topical offering is prepared for an individual patient. A specified blood-derived fraction of CGF is blended with a formulated cream base, then supplied with individual handling instructions.
It is not raw blood in a jar. It is also not made entirely from the patient's biology: the base and its ingredients remain part of the finished product.
A 2019 pilot study investigated a particular PRP-containing topical formulation after electroporation and reported changes in collagen-related measures. This early work does not prove the same benefit for every cream.
The appeal is a genuinely patient-specific preparation and a clear role in the care plan. Its ingredients, intended application, storage and expiry need to be understood before it goes home.
How do the new options fit with PRP and Autologous Exosomes?
PRP remains a distinct service, particularly when patients ask about the platelet-based approach they already know. A placebo-controlled trial of PRP for androgenetic alopecia supports discussion for suitable pattern hair loss, not every form of thinning.
Our autologous Exosome protocol adds a filtration step to plasma processing. Its technology description describes a mixed concentrate, including extracellular vesicles and other components. We do not equate that with a purified exosome product.
APAG adds a volume-focused format with CGF's regenerative properties. LPCGF adds another skin-focused preparation. The cream adds a topical format.
Skin quality, scars and the limits of one treatment
A fine-line concern is different from an indented acne scar. A raised surgical scar is different again. We do not use the phrase regenerative therapy to flatten those distinctions.
For scar concerns, the consultation should establish the scar type, healing stage and appropriate main treatment. An autologous preparation may be considered as an adjunct. The goal is possible improvement in appearance, not a promise to erase every scar.
The same principle applies to stretch marks and concerns on the neck, décolleté or hands: a new preparation is not a substitute for assessing the skin and discussing realistic outcomes.
Why overseas visitors may encounter different options at home
Some patients will know PRP but not the terms APAG or LPCGF. That does not mean the procedures are unavailable throughout their home country.
In Australia, TGA rules distinguish preparations and processing conditions; they do not impose a blanket PRP/PRF ban. In Singapore, non-listed aesthetic procedures require classification before routine use outside an approved trial.
For visitors from Germany, Spain or Italy, a blood-derived cream raises a different issue: EU cosmetic rules prohibit human-origin ingredients in cosmetics. This must not be confused with the rules governing medical procedures. In the United States, FDA approval of microneedling devices does not extend to delivering PRP or topical products.
Local practice, product classification and the treatment indication need individual checking. International patients should also plan follow-up and clarify transport requirements before accepting a take-home preparation.
The next chapter in SOMA's regenerative-care series
This launch begins a patient-education series covering the differences between blood-derived preparations, how personalised topical care works, and the questions to ask when choosing a provider.
SŌMA and our physicians hold A4M and ISSCA accreditations, and we want patients to understand the practical details of their care: who is treating them, what is being prepared, which benefit is supported and what happens after the appointment.
Frequently asked questions
Do I need all three new treatments?
No. The new treatments provide different options, not a mandatory package. A patient considering volume support has a different decision from someone asking about a topical routine.
Are the new therapies better than PRP?
They use different preparation methods, higher concentrations, and different types of biomaterial derived from plasma, and they serve different roles. A claim of superiority requires a direct comparison for the same clinical problem, not simply a new name.
Can I have a treatment during a short Bali visit?
An assessment can establish what is practical. Treatment timing, expected short-term effects and access to follow-up should be considered before booking around travel.
Is the cream suitable for everyone?
No. The skin condition, the base ingredients and the ability to follow handling and storage instructions all matter. A personalised product can still be unsuitable for an individual patient.
Start with your goal
Tell us what you want to improve: skin quality, hair density, scar appearance, or facial volume. Contact SOMA for an assessment, or explore the SŌMA blog for the rest of the series.
This article introduces treatment options, not a guarantee of benefit or an individual recommendation. Each service requires clinical assessment and an appropriate, permitted protocol.
